cirrhosis

pass the torch deal sell buy acquisition
Biotech

Gilead pays $4.3B for CymaBay's late-stage liver disease med

Gilead is bolstering its liver disease portfolio with the $4.3 billion acquisition of CymaBay, specifically for the liver disease med seladelpar.
Annalee Armstrong Feb 12, 2024 9:01am
liver NASH NAFLD

Akero sinks as midphase cirrhosis fail sparks flash NASH crash

Oct 10, 2023 8:00am
plan B fail reroute road path trail miss

Galecto cans lung fibrosis med after ph. 2 fail, pivots to liver

Aug 15, 2023 7:30am
Pliant Therapeutics

Novartis bets $80M on Pliant's preclinical NASH prospect

Oct 23, 2019 8:00am
Headshot of Aoife Brennan CEO of Synlogic

Synlogic scraps ammonia-lowering drug after early phase fail

Aug 20, 2019 8:08am
nasdaq screens1

Galectin plunges on NASH cirrhosis midstage miss

Dec 5, 2017 9:40pm